Evaluation of QIAreach QuantiFERON-TB lateral-flow nanoparticle fluorescence assay for TB infection diagnosis among TB household contacts in three high-burden settings.

ABSTRACT:

Background

Tuberculosis infection (TBI) testing, and treatment are fundamental to achieve TB elimination. TBI testing among close or household contacts (HHCs) has been limited, in part due to perceived complexity and high operational cost. We evaluated the performance of a new near-patient and field-based QIAreach QuantiFERON-TB (QIAreach) against QuantiFERON-TB-Gold-Plus (QFT-Plus) among HHCs of people with TB.

Methods

A cross-sectional study was conducted from July 2021 to September 2022 in Lesotho, South Africa and Tanzania. Blood samples were collected from HHCs for paired QFT-Plus and QIAreach processing, testing and interpretation. To evaluate the performance of QIAreach against QFT-Plus as a reference, we determined the: i) prevalence of TBI, ii) total concordance usi

SUBMITTER: Ntshiqa T 

PROVIDER: S-EPMC12448356 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature